{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:05:51Z","timestamp":1790762751169,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007343","name":"Universit\u00e0 degli Studi di Brescia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007343","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interstitial lung disease (ILD) represents one of the most severe extra-muscular features of idiopathic inflammatory myositis (IIM). We aimed to identify any clinical and serological predictors of ILD in a monocentric cohort of 165 IIM patients.<\/jats:p><jats:p>ILD+ patients were defined as having restrictive impairment in lung function tests and signs of ILD at chest high-resolution computed tomography (HRCT). Available HRCT images were centralized and classified in different ILD patterns: non-specific interstitial pneumonia (NSIP), organizing pneumonia (OP), usual interstitial pneumonia-like (UIP), indeterminate for UIP, and interstitial lung abnormalities (ILA). Lung function test data were recorded at onset, at 1 and 5\u00a0years after ILD diagnosis.<\/jats:p><jats:p>ILD was found in 52 IIM patients (31.5%): 46.2% was affected by anti-synthetase syndrome (ARS), 21% by polymyositis (PM), 19% by dermatomyositis (DM), and 13.5% by overlap myositis. Most of ILD+ showed NSIP (31.9%), OP (19%), indeterminate for UIP (19%), and UIP (12.8%) patterns. At multivariate analysis, ILD was predicted by anti-Ro52 (<jats:italic>p<\/jats:italic>: 0.0026) and dyspnea (<jats:italic>p<\/jats:italic>: 0.015) at IIM onset. Most of ILD onset within is 12\u00a0months after IIM. In five cases, ILD occurs after 12\u00a0months since IIM diagnosis: these patients more frequently show dry cough and anti-Ku antibodies. Anti-Ro52\u00a0+\u00a0ILD patients showed a significant increase of DLCO at 1 and 5\u00a0years of follow-up, compared with anti-Ro52 negative cases.<\/jats:p><jats:p>ILD occurs in about one third of IIM and was predicted by dyspnea at onset and anti-Ro52 antibodies. Anti-Ro52 defines a subgroup of ILD showing a significant improvement of DLCO during follow-up. <\/jats:p><jats:p>This retrospective study has been approved by local ethic committee (ASST-Spedali Civili of Brescia, Italy); protocol number: NP3511<\/jats:p>","DOI":"10.1007\/s12016-020-08814-5","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T09:10:40Z","timestamp":1604394640000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis"],"prefix":"10.1007","volume":"60","author":[{"given":"Tamara","family":"Vojinovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cavazzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ceruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Fredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Modina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialma","family":"Berlendis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3678-6124","authenticated-orcid":false,"given":"Franco","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"8814_CR1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fmed.2019.00326","volume":"6","author":"B Harvier","year":"2020","unstructured":"Harvier B, Uzunhan Y (2020) Inflammatory myopathy-related interstitial lung disease: From pathophysiology to treatment. Front Med 6:326","journal-title":"Front Med"},{"key":"8814_CR2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/157339710791330740","volume":"6","author":"LA Saketkoo","year":"2010","unstructured":"Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Oddis CV (2010) Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev 6:108\u2013119","journal-title":"Curr Rheumatol Rev"},{"key":"8814_CR3","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1097\/MD.0000000000001144","volume":"94","author":"L Cavagna","year":"2015","unstructured":"Cavagna L, Nuno L, Scire\u2019 CA, Govoni M, Lopez-Longo FJ, Franceschini F et al (2015) Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome results from an international retrospective multicenter study. Medicine 94:e1144","journal-title":"Medicine"},{"key":"8814_CR4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3390\/jcm8112013","volume":"8","author":"L Cavagna","year":"2019","unstructured":"Cavagna L, Trallero-Araguas E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E et al (2019) Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med 8:2013","journal-title":"J Clin Med"},{"key":"8814_CR5","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.rmed.2007.02.017","volume":"101","author":"JW Hu","year":"2007","unstructured":"Hu JW, Kim DS, Lee CK, Yoo B, Bum SJ, Kitaichi M, Colby TV (2007) Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 101:1761\u20131769","journal-title":"Respir Med"},{"key":"8814_CR6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.resinv.2016.08.007","volume":"55","author":"N Yoshida","year":"2017","unstructured":"Yoshida N, Okamoto M, Kaieda S, Fujimoto K, Ebata T, Tajiri M et al (2017) Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis\/dermatomyositis-associated interstitial lung disease. Respir Invest 55:24\u201332","journal-title":"Respir Invest"},{"key":"8814_CR7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/CM9.0000000000000691","volume":"133","author":"YZ Gan","year":"2020","unstructured":"Gan YZ, Zhang LH, Ma L, Sun F, Li YH, An Y, Li ZG, Yi H (2020) Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis. Chinese Med J 133:644\u2013649","journal-title":"Chinese Med J"},{"key":"8814_CR8","doi-asserted-by":"crossref","unstructured":"Labrador-Horrillo M, Martinez MA, Selva-O\u2019Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. (2014) Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Re 290797","DOI":"10.1155\/2014\/290797"},{"key":"8814_CR9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","volume":"44","author":"S Moghadam-Kia","year":"2017","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R (2017) Antimelanoma differentiation-associated Gene 5 antibody: Expanding the clinical spectrum in North American patients with Dermatomyositis. J Rheumatol 44:319\u2013325","journal-title":"J Rheumatol"},{"key":"8814_CR10","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","volume":"65","author":"Z Chen","year":"2013","unstructured":"Chen Z, Cao M, PlanaZ, Liang J, Cai H, Kuwana M, Sun L. MN (2013) Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthr Care Res 65:1316\u20131324","journal-title":"Arthr Care Res"},{"key":"8814_CR11","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, Kuwana M (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 60:2193\u20132200","journal-title":"Arthritis Rheum"},{"key":"8814_CR12","doi-asserted-by":"publisher","unstructured":"Zuo Y, Yie L, Liu M, Li S, Liu W, Chen F, et al (2020) Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keaa034","DOI":"10.1093\/rheumatology\/keaa034"},{"key":"8814_CR13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2796.2011.02459.x","volume":"271","author":"M Fathi","year":"2012","unstructured":"Fathi M, Barbasso Helmers S, Lundberg IE (2012) KL-6: A serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med 271:589\u2013597","journal-title":"J Intern Med"},{"key":"8814_CR14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344\u2013347","journal-title":"N Engl J Med"},{"key":"8814_CR15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1297-319X(03)00012-5","volume":"70","author":"A Imbert-Masseau","year":"2003","unstructured":"Imbert-Masseau A, Hamidou M, Agard C, Groulleau JY, Cherin P (2003) Antisynthetase syndrome. Joint Bone Spine 70:161\u2013168","journal-title":"Joint Bone Spine"},{"key":"8814_CR16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-0032-1329197","volume":"32","author":"MM Dimachkie","year":"2012","unstructured":"Dimachkie MM, Barohn RJ (2012) Inclusion body myositis. Semin Neurol 32:237\u2013245","journal-title":"Semin Neurol"},{"key":"8814_CR17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","volume":"28","author":"Y Allenbach","year":"2018","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W (2018) Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016. Neuromuscul Disord 28:87\u201399","journal-title":"Neuromuscul Disord"},{"key":"8814_CR18","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) Classification criteria for systemic sclerosis: An ACR-EULAR collaborative initiative. Arthr Rheum 65:2737\u20132747","journal-title":"Arthr Rheum"},{"key":"8814_CR19","first-page":"1400","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbaden K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R et al (2019) European League against rheumatism\/American College of Rheumatology classification criteria for Systemic Lupus Erythematosus 71:1400\u20131412","journal-title":"European League against rheumatism\/American College of Rheumatology classification criteria for Systemic Lupus Erythematosus"},{"key":"8814_CR20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjogren\u2019s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554\u2013558","journal-title":"Ann Rheum Dis"},{"key":"8814_CR21","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Teogi T, Silman AJ, Funovitis J, Felson DT, Bingham CO III et al (2010) 2010 Rheumatoid arthritis classification criteria. Arhritis Rheum 62:2569\u20132581","journal-title":"Arhritis Rheum"},{"issue":"Suppl V","key":"8814_CR22","first-page":"v1","volume":"63","author":"B Bradley","year":"2008","unstructured":"Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK et al (2008) Interstitial Lung Disease Guideline. Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63(Suppl V):v1\u2013v58","journal-title":"Thorax"},{"key":"8814_CR23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG et al (2013) An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733\u2013748","journal-title":"Am J Respir Crit Care Med"},{"key":"8814_CR24","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1148\/rg.2015140334","volume":"35","author":"N Sverzellati","year":"2015","unstructured":"Sverzellati N, Lynch DA, Hansell DM, Johkoh T, King TE Jr, Travis WD (2015) American Thoracic Society \u2013 European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. Radiographics 35:1849\u20131871","journal-title":"Radiographics"},{"key":"8814_CR25","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 198:e44\u2013e68","journal-title":"Am J Respir Crit Care Med"},{"key":"8814_CR26","doi-asserted-by":"crossref","first-page":"405956","DOI":"10.1155\/2014\/405956","volume":"2014","author":"L Musset","year":"2014","unstructured":"Musset L, Miyara M, Benveniste O, Charuel JL, Shikhman A, Boyer O et al (2014) Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies. J Immunol Res 2014:405956","journal-title":"J Immunol Res"},{"key":"8814_CR27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","volume":"15","author":"L Musset","year":"2016","unstructured":"Musset L, Allenbach Y, Benveniste O, Boyer O, Bossuyt X, Bentow C et al (2016) Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmun Rev 15:983\u2013993","journal-title":"Autoimmun Rev"},{"key":"8814_CR28","doi-asserted-by":"crossref","first-page":"e000507","DOI":"10.1136\/rmdopen-2017-000507","volume":"14","author":"M Bottai","year":"2017","unstructured":"Bottai M, Triamlund A, Santoni G, Werth VP, Pilkington C, de Visser M et al (2017) EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: A methodology report. RMD Open 14:e000507","journal-title":"RMD Open"},{"key":"8814_CR29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12016-016-8527-x","volume":"52","author":"A Ceribelli","year":"2017","unstructured":"Ceribelli A, De Santis M, Isailovic N, Gershwin NE, Selmi C (2017) The immune response and the pathogenesis of idiopathic inflammatory myositis: A critical review. Clin Rev Allergy Immunol 52:58\u201370","journal-title":"Clin Rev Allergy Immunol"},{"key":"8814_CR30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.22293","volume":"56","author":"P Englund","year":"2007","unstructured":"Englund P, Wahlstr\u00f6m J, Fathi M, Rasmussen E, Grunewald J, Tornling G et al (2007) Restricted T cell receptor BV gene usage in the lungs and muscles of patients with idiopathic inflammatory myopathies. Arthritis Rheum 56:372\u2013383","journal-title":"Arthritis Rheum"},{"key":"8814_CR31","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"56","author":"T Gono","year":"2014","unstructured":"Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M et al (2014) Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology 56:2196\u20132203","journal-title":"Rheumatology"},{"key":"8814_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13154","author":"T Shimizu","year":"2020","unstructured":"Shimizu T, Koga T, Furukawa K, Horai Y (2020) IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis\/dermatomyositis. J Intern med. https:\/\/doi.org\/10.1111\/joim.13154","journal-title":"J Intern med"},{"key":"8814_CR33","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","volume":"68","author":"S Moghadam-Kia","year":"2016","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R (2016) Anti-melanoma differentiation\u2013associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthr Care Res 68:689\u2013694","journal-title":"Arthr Care Res"},{"key":"8814_CR34","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","volume":"65","author":"JC Hall","year":"2013","unstructured":"Hall JC, Casciola-Rosen L, Samedy L-A et al (2013) Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: Expanding the clinical spectrum. Arthritis Care Res 65:1307\u20131315","journal-title":"Arthritis Care Res"},{"key":"8814_CR35","first-page":"891","volume":"32","author":"A Ceribelli","year":"2014","unstructured":"Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis. Clin Exp Rheum 32:891\u2013897","journal-title":"Clin Exp Rheum"},{"key":"8814_CR36","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","volume":"41","author":"I Marie","year":"2012","unstructured":"Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard J-F et al (2012) Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 41:890\u2013899","journal-title":"Semin Arthritis Rheum"},{"key":"8814_CR37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08916930600623791","volume":"39","author":"R La Corte","year":"2006","unstructured":"La Corte R, Lo Monaco A, Locaputo A, Dolzani F, Trotta F (2006) In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 39:249\u2013253","journal-title":"Autoimmunity"},{"key":"8814_CR38","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","volume":"44","author":"J Shi","year":"2017","unstructured":"Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X, Wang G (2017) Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatology 44:1051\u20131057","journal-title":"J Rheumatology"},{"key":"8814_CR39","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","volume":"78","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG et al (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78:988\u2013995","journal-title":"Ann Rheum Dis"},{"key":"8814_CR40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP et al (2019) Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 101:48\u201355","journal-title":"J Autoimmun"},{"key":"8814_CR41","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2018-214439","volume":"78","author":"L Spielmann","year":"2019","unstructured":"Spielmann L, Nespola B, Severac F, Andres E, Kessler R, Guffroy A et al (2019) Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes. Ann Rheum Dis 78:1101\u20131106","journal-title":"Ann Rheum Dis"},{"key":"8814_CR42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s40674-018-0110-6","volume":"5","author":"C Shappley","year":"2019","unstructured":"Shappley C, Paik JJ, Saketkoo LA (2019) Myositis-related interstitial lung diseases: diagnostic features, treatment, and complications. Curr Treatm Opt Rheumatol 5:56\u201383","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"8814_CR43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas A, Silver RM, Arrossi AV, Highland KB (2020) Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 8:304\u2013320","journal-title":"Lancet Respir Med"},{"key":"8814_CR44","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","volume":"65","author":"I Marie","year":"2013","unstructured":"Marie I, Josse S, Hatron PY, Dominique S, Hachulla E, Janvresse A et al (2013) Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res 65:800\u2013808","journal-title":"Arthritis Care Res"},{"key":"8814_CR45","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1164\/rccm.201903-0511OC","volume":"200","author":"BD Hobbs","year":"2019","unstructured":"Hobbs BD, Putman RK, Araki T, Nishino M, Gudmunsson G, Gudnason V et al (2019) Overlap of genetic risk between interstitial lung abnormalities and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 200:1402\u20131413","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-020-08814-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-020-08814-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-020-08814-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T09:32:18Z","timestamp":1611221538000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-020-08814-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["8814"],"URL":"https:\/\/doi.org\/10.1007\/s12016-020-08814-5","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"21 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This retrospective study has been approved by local ethic committee (ASST-Spedali Civili of Brescia, Italy); protocol number: NP3511.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Data were obtained from medical charts: every patient signed our institutional consent for the management of personal data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}